13D Filing: Broadfin Capital and Recro Pharma Inc. (REPH)

Page 8 of 9 – SEC Filing

Exhibit A

AGREEMENT

The undersigned agree that
this Schedule 13D/A, dated December 4, 2017, relating to the Common Stock par value $0.01 of Recro Pharma, Inc. shall be filed
on behalf of the undersigned.

December 4, 2017

(Date)

BROADFIN CAPITAL, LLC

By: /s/ Kevin Kotler

Kevin Kotler, Managing Member

KEVIN KOTLER

/s/ Kevin Kotler

BROADFIND HEALTHCARE MASTER FUND, LTD.

By: /s/ Kevin Kotler

Kevin Kotler, Director

Follow Societal Cdmo Inc. (NASDAQ:SCTL)